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Abstract
Background: Anti-cancer chemotherapy can be simultaneously lymphodepleting and immunostimulatory. Pre-clinical
models clearly demonstrate that chemotherapy can synergize with immunotherapy, raising the question how the immune
system can be mobilized to generate anti-tumor immune responses in the context of chemotherapy.
Methods and Findings: We used a mouse model of malignant mesothelioma, AB1-HA, to investigate T cell-dependent
tumor resolution after chemotherapy. Established AB1-HA tumors were cured by a single dose of cyclophosphamide in a
CD8 T cell- and NK cell-dependent manner. This treatment was associated with an IFN-a/b response and a profound
negative impact on the anti-tumor and total CD8 T cell responses. Despite this negative effect, CD8 T cells were essential for
curative responses. The important effector molecules used by the anti-tumor immune response included IFN-c and TRAIL.
The importance of TRAIL was supported by experiments in nude mice where the lack of functional T cells could be
compensated by agonistic anti-TRAIL-receptor (DR5) antibodies.
Conclusion: The data support a model in which chemotherapy sensitizes tumor cells for T cell-, and possibly NK cell-,
mediated apoptosis. A key role of tumor cell sensitization to immune attack is supported by the role of TRAIL in tumor
resolution and explains the paradox of successful CD8 T cell-dependent anti-tumor responses in the absence of CD8 T cell
expansion.
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Introduction
Tumor antigens are cross-presented to the immune system
[1,2,3]. However, the ensuing anti-tumor CD8 T cell response is
usually not effective and fails to control tumor growth. Indeed, the
immunological outcome of antigen cross-presentation is deter-
mined by the context in which tumor antigens are presented.
Altering that context is an important goal for anti-cancer
immunotherapy [4,5,6]. Cytotoxic chemotherapy can play a role
in this process since apoptotic tumor cell death can be an
immunostimulatory event (‘immunogenic cell death’) [7,8,9],
potentially adding an immunostimulatory signal to cross-presented
antigens. An immune priming effect has now been shown for
several chemotherapeutic drugs, including gemcitabine [4,10] and
doxorubicin [7]. As a result, chemo- and immunotherapy are no
longer considered to be a priori antagonistic [11] and the concept of
combined chemo-immuno therapy is receiving more attention
[11,12,13]. However, the notion that chemotherapy and anti-
tumor T cell responses can be synergistic must be reconciled with
the fact that many chemotherapeutic drugs deplete lymphocytes
[14]. In fact, lymphodepletion after chemotherapy was the main
reason why chemo- and immunotherapy were seen as antagonis-
tic. The growing insight that chemotherapy can be immunosti-
mulatory presents a paradox: how are effective anti-tumor T cell
responses generated under lymphodepleting conditions? The
present study aims to address the paradoxical relationship between
immunogenicity and lymphodepletion. To study this, we have
used a mouse model of malignant mesothelioma (AB1-HA), which
is sensitive to both chemotherapy and immunotherapy [4,15,16],
in combination with the chemotherapeutic drug cyclophospha-
mide (CY), since CY treatment is associated with innate
and adaptive immune activation [17,18,19,20,21]. The AB1-HA
tumor cell line was generated by transfection of the asbestos-
PLoS ONE | www.plosone.org 1 September 2009 | Volume 4 | Issue 9 | e6982induced AB1 tumor cell line [16] with the influenza virus HA gene
[15]. The tumor-expressed HA protein allows us to monitor the
anti-tumor T cell response [5,15,22], but it does not impact on
tumor immunogenicity, as evidenced by the fact that AB1-HA
cured mice are also protected against re-challenge with the
parental AB1 line [23].
The immuno-stimulatory properties of CY (Cytoxan
TM) have
been known for decades. In the 1980s, it was shown that CY
depleted cycling suppressor T cells, now known as regulatory T
cells, and thereby activated anti-tumor CD8 T cells [24].
However, we have recently shown that the anti-tumor efficacy of
CY in the AB1-HA model cannot be explained by regulatory T
cell depletion alone [18]. Here, we show that CY kills tumor cells
by apoptosis and that it has a CD8 T cell- and NK cell-dependent
anti-tumor effect in the AB1-HA tumor model. At the same time,
CY has a strong negative effect on T cell proliferation, limiting the
potential expansion of anti-tumor CD8 T cells, raising the
question how a CD8 T cell-dependent anti-tumor response
functions without T cell expansion. We found that the anti-tumor
immune response depended on different effector molecules to
eliminate the tumor: IFN-c and TRAIL. The role of TRAIL was
supported by data showing that agonistic anti-TRAIL-receptor
(DR5) antibodies enhanced the effects of CY in athymic nude
mice. Thus, a DR5-agonist compensates for the lack of functional
T cell in nude mice. The role of TRAIL suggests that the efficacy
of CY can be explained by tumor cell sensitization for T cell and/
or NK cell apoptosis. A model in which CY sensitizes tumor cells
for TRAIL-mediated death may help explain the chemotherapy
paradox, since such a model emphasizes tumor cell susceptibility
rather than expansion of anti-tumor CD8 T cells.
Results
The objective of this study was to investigate the potential
discrepancy between lymphodepleting anti-tumor chemotherapy
and the anti-tumor immune responses that are linked to successful
chemotherapy [11,25]. To test this, we used a murine mesothe-
lioma model (AB1-HA) that is sensitive to both chemotherapy and
immunotherapy [1,4,18], in combination with the DNA cross-
linker cyclophosphamide (CY).
Apoptotic cell death after maphosphamide treatment of
tumor cells
As we have recently shown [18], AB1-HA murine mesothelioma
cells are killed by maphosphamide, which is the active metabolite
of CY. To further determine how CY kills tumor cells, AB1-HA
cells were treated with the active metabolite maphosphamide at
different concentrations for 24 hours. Induction of apoptosis was
evaluated using the fluorescent FAM-VAD-fmk pan-caspase
staining reagent (FLIVO), which binds activated caspases [26].
In vitro exposure of tumor cells to maphosphamide increased the
proportion of FAM-VAD-fmk reactive cells in a dose-dependent
manner, suggesting that cell death was associated with pan-caspase
activation and hence apoptosis (Figure 1). Similarly, FAM-VAD-
fmk staining cells were observed after in vivo treatment of tumor-
bearing mice with cyclophosphamide (data not shown). Thus, as
we show here, the CY metabolite maphosphamide induces
apoptosis in AB1-HA tumor cells, providing a plausible explana-
tion for the in vitro cytotoxic effect of maphosphamide and the in
vivo anti-tumor effect of CY in athymic nude mice, as previously
demonstrated [18].
Immunogenicity of CY chemotherapy
Apoptotic tumor cell death can be immune-stimulatory [7].
Thus, to evaluate the immune effects of CY-induced tumor cell
apoptosis, we analyzed changes in gene expression within CY-
treated tumors using real time PCR SuperArrays, allowing
simultaneous analysis of 84 cytokine genes using real-time PCR.
Preliminary data indicate that several pro-inflammatory genes
were upregulated in CY-treated tumors, including type-I IFNs
(IFN-a4 and IFN-b1) but also IL-1a, IL-19, IL-2 and OX40L
(Van der Most, unpublished data). Type-I IFN production after
CY treatment was further analyzed by measuring the expression
levels of Ly6AE on CD8 T cells. Ly6AE upregulation on T cells is
a very early non-antigen-specific (bystander) response of T cells to
IFN-exposure [27,28] and can therefore serve as a surrogate for
type-I IFN (IFN-a/b) production. Indeed, we have recently
confirmed that Ly6AE-upregulation on CD8 T cells occurs in a
strictly IFN-a/b-dependent manner after AB1-HA tumor treat-
ment with the TLR3 and TLR7 agonists poly-I:C and imiquimod
[5,23]. Therefore, to assess IFN-a/b production, we measured
Ly6AE expression on peripheral blood CD8 T cells harvested
three days after administration of CY (150 mg/kg) in AB1-HA
tumor-bearing mice. We found that CY treatment resulted in an
upregulation of Ly6AE expression on the majority of CD8 T cells
in the PBL pool when compared to untreated tumor-bearing mice
(Figure 2A), consistent with systemic exposure of the CD8 T cells
to IFN-a/b. The level of upregulation was similar to that observed
with (intratumoral) poly-I:C injection (Figure 2A). Neutralization
of type-I IFNs, using an anti-IFN-a/b serum, completely inhibited
Ly6AE upregulation on peripheral blood CD8 T cells (Figure 2A),
Figure 1. The CY metabolite maphosphamide kills by inducing apoptosis. AB1-HA tumor cells were treated with different doses of
maphosphamide for 24 h and stained with FLIVO reagent.
doi:10.1371/journal.pone.0006982.g001
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expression is a bona fide marker for systemic type-I IFN release
[5,23]. To evaluate the longevity of the IFN-a/b response, we
analyzed Ly6AE expression on day 10 after CY injection in the
tumor draining and non-draining lymph nodes. The results clearly
show sustained Ly6AE upregulation on CD8 T cells in both
draining and non-draining lymph nodes (Figure 2B), demon-
strating that CY injection results in long-lasting and systemic type-
I IFN release. Therefore, the combined data suggest that CY-
injection in tumor-bearing mice results in systemic immune
activation, consistent with the concept of immunogenic cell death
[7,18] and consistent with previously reported data [17,29].
Anti-tumor responses depend on CD8 T cells but not on
IFN-ab
CY has a strong CD8 T cell-dependent anti-tumor effect in
AB1-HA tumor-bearing mice, routinely leading to 75–100% cure
rate when small (i.e., just palpable) tumors are treated (Figure 3A),
confirming our previous data [18], whereas CD8 depletion alone
had a weak effect accelarating tumor growth (P=0.07, data not
shown). As we demonstrated previously, CY treatment in tumor-
bearing athymic nude mice (which lack functional T cells) only
had a transient anti-tumor effect and did not result in any curative
anti-tumor responses [18]. Thus, T cells play an essential role in
achieving cures. Since CY treatment is associated with an IFN-a/
b response and because primary CD8 T cell responses to apoptotic
cells and cross-presented antigens are type-I IFN-dependent
[8,30], we hypothesized that the type-I IFN response could be
responsible for priming the anti-tumor CD8 T cell response. This
was tested by in vivo neutralization of IFN-a/b. We found that the
anti-tumor efficacy of CY was only marginally affected by type-I
IFN neutralization (Figure 3B), indicating that the CY-induced
anti-tumor CD8 T cell response was not dependent on IFN-a/b.
As a positive control for the efficiency of in vivo IFN-a/b-
neutralization, we have shown that poly-I:C-mediated anti-tumor
responses were abrogated using this anti-IFN-a/b treatment [5].
Thus, our data suggest that the CY-induced anti-tumor T cell
response is type-I IFN independent and may therefore not be a de
novo response because such a response would be type-I IFN-
dependent [8]. Instead, we reasoned that CY could make existing
responses more effective, either by expanding tumor-specific CD8
T cells or by increasing the sensitivity of tumor cells to T cell-
mediated apoptosis. To test this, we further studied anti-tumor
CD8 T cell responses after CY treatment.
Impaired CD8 T cell responses after CY treatment
CY is a cytotoxic and lymphodepleting drug. A single dose of
CY (150 mg/kg) resulted in a 75% reduction of splenic cellularity
[18] as well as of total CD8 T cell numbers (data not shown)
Thus, expansion of anti-tumor CD8 T cells after CY chemother-
apy seems paradoxical. To study this, we characterized total and
tumor-specific CD8 T cell responses after CY treatment, using
three different experimental approaches. First, we assessed CD8 T
cell proliferation in the tumor-draining lymph nodes after CY
treatment by intracellular Ki-67 staining. Ki-67 is a nuclear
marker that is upregulated in cycling cells [18,31,32]. Interestingly,
CY treatment selectively depleted cycling cells, as shown by the
almost complete absence of Ki-67
hi CD8 T cells three days after a
single CY injection (Figure 4A). We have recently reported
similar findings for CD4 T cells and foxp3
+ CD4
+ regulatory T
cells [18]. This specific loss of Ki-67
hi T cells was not seen with a
different cytotoxic drug, gemcitabine (GEM) (Figure 4A), despite
the fact that GEM causes lymphodepletion in mice [14]. Since
both drugs are cytotoxic, the difference between CY and GEM
may be one of kinetics, in which the CY-mediated T cell
proliferation arrest is more long-lived. Second, to assess to the
impact of CY on the tumor-specific CD8 T cell response, we
adoptively transferred TCR-transgenic CD8 T cells into
CY treated mice. Clone 4 transgenic CD8 T cells recognize a
Figure 2. Type-I IFN production assessed by Ly6AE upregula-
tion on CD8 T cells. Data shown are representative histograms
displaying the shift in staining intensity from isotype control to Ly6AE
hi
CD8 T cells from one of three tumor-bearing mice per treatment group.
Poly(I:C) was used as a positive control for Ly6AE expression. (A) From
top to bottom: Ly6AE on CD8 T cells in PBS-treated mice, CY-treated
mice, CY + anti-IFN-a/b treated mice, poly-I:C treated mice and isotype
control staining (tinted curve), in PBL samples, day 3 after i.p. CY
injection. (B) Type-I IFN responses are long-lived and systemic. Ly6AE
expression in tumor draining and non-draining lymph nodes analyzed
at day 10 post CY injection. CY-treated mice and untreated mice are
compared.
doi:10.1371/journal.pone.0006982.g002
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d-restricted epitope from the influenza virus HA protein which is
expressed as a tumor neo-antigen in AB1-HA cells [15]. Ten
million CFSE-labeled tumor-specific transgenic CD8 T cells were
adoptively transferred into mice at day 7 after tumor cell
inoculation. Mice were treated with CY (150 mg/kg) at day 9
and lymphocytes were isolated from the tumor-draining and non-
draining lymph nodes at day 14 (i.e., 5 days after CY injection and
7 days after adoptive transfer). Confirming previous work
employing this same assay [1], we observed robust proliferation
of tumor-specific CD8 T cells in the tumor-draining lymph nodes
of untreated control tumor-bearing mice, as can be inferred from
the serial dilution of CFSE dye intensity (Figure 4B). However,
both the recovery of tumor-specific transgenic T cells as well as
proliferation of these cells (assessed by serial CFSE dilution) were
significantly reduced in the draining lymph nodes from CY-treated
mice (Figure 4B). These findings are consistent with the notion
that CY has a negative effect on T cell proliferation. Third, to
further define the specificity of CD8 T cell responses after CY
treatment we used a MHC class I pentamer specific for the K
d-
restricted HA epitope to visualize the endogenous response to the
HA epitope. Thus, these experiments were done without adoptive
T cell transfer. Since CY-induced lymphopenia is transient, with
splenic cellularity recovering within 10 days after treatment (data
not shown), we reasoned that early inhibition of T cell
proliferation could be followed by recovery of the anti-tumor
CD8 T cell response. Therefore, we measured CD8 T cell
responses at day 10 after CY injection. Low frequencies of
pentamer-positive HA-specific CD8 T cells were measured in the
draining lymph nodes of both untreated and CY-treated tumor-
bearing mice (Figure 4C) and there were no significant
differences, although there was a trend towards lower frequencies
of pentamer-positive cells after CY treatment (P=0.06). Pheno-
typic characterization of pentamer+ cells using the cytotoxicity
marker CD43 [33] revealed that in untreated tumor-bearing mice,
both CD43
hi and CD43
lo pentamer+ tumor specific CD8 T cells
were present (Figure 4D), whereas the small populations of
pentamer+ CD8 T cells in CY-treated mice appeared to be
CD43
lo. Overall, these data suggests that these T cells do not
possess a highly activated and cytotoxic phenotype. However,
despite this lack of CD8 T cell expansion, we found that mice that
were cured through CY treatment invariably resisted rechallenge
with AB1-HA tumor cells (n=20, data not shown), which
indicates that the CD8 T cell response that was mobilized by CY
treatment eventually generated tumor-specific memory.
Figure 3. Role of CD8 T cells and type-I IFN in CY-driven anti-tumor efficacy. (A) Anti-tumor responses depend on CD8
+ T cells. Tumor-
bearing mice were treated with CY at day 10 after tumor inoculation (day 0) and anti-CD8 mAbs (150 mg) were injected at days 21, 0, 2, 4, 6 and 8
with respect to CY treatment. Data shown are mean6SEM (n=5) from one representative experiment from a total of three experiments with a total
of 15 mice. * P,0.05 when CY is compared with CY + anti-CD8. (B) In vivo IFN-a/b neutralization marginally affects tumor growth in CY-treated mice.
BALB/c mice bearing AB1-HA tumors were given IFN-a/b blocking antibody on days 21, +2, +4 with respect to CY treatment. Tumors were inoculated
at day 0 and were treated with CY at day 9. Data shown are mean6SEM (n=5) from one experiment. ns=not-significant.
doi:10.1371/journal.pone.0006982.g003
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PLoS ONE | www.plosone.org 4 September 2009 | Volume 4 | Issue 9 | e6982Figure 4. Impaired proliferation of CD8 T cells after CY treatment. (A) Draining lymph node cells from tumor-bearing mice treated with
saline, CY or gemcitabine (GEM) at day 10 post inoculation were analyzed for Ki-67 expression three days later. Cells shown were gated such that
CD8
neg cells are CD4 T cells. Data shown in lower panel are mean6SEM (n=3) from one experiment. ** P,0.01 when PBS is compared with CY
(unpaired t test). (B) Adoptively transferred transgenic CD8 T cells fail to proliferate in CY-treated mice. CFSE-labeled HA-specific clone 4 cells were
transferred into tumor bearing mice two days before PBS or CY injection and were harvested 7 days later and stained for CD8 expression. Cells shown
are gated as CD8
+. Data shown in lower panel are mean6SEM (n=3) from one experiment. * P,0.05 when PBS is compared with CY (unpaired t test).
(C) HA-specific MHC class I pentamer staining in untreated and CY-treated tumor-bearing mice. Data shown are frequencies of pentamer+ CD8 T cells
per total CD8 T cells in tumor-draining lymph nodes at day 10 post CY injection. ns=not significant (P=0.06, unpaired t test). (D) CD43 (clone 1B11)
expression on pentamer
+ CD8 T cells in tumor-draining lymph nodes. Cells shown are gated on CD8
+ cells. Representative plots are shown.
doi:10.1371/journal.pone.0006982.g004
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discrepancy between the key role of CD8 T cells in tumor
resolution and the strong anti-proliferative affects of CY on CD8 T
cells.
Antitumor responses depend on IFN-c and perforin
To address the question how CD8 T cells can be the key
mediators for tumor resolution under conditions that limit T cell
proliferation, we set out to delineate the effector mechanisms
responsible for the CY-induced anti-tumor immune responses. We
evaluated the roles of different CD8 T cell effector mechanisms
using gene-targeted mice lacking specific CD8 T cell effector
functions, i.e., IFN-c and/or perforin. To define the role of IFN-c,
we analyzed tumor growth in IFN-c knock-out mice and found
that IFN-c deficiency prevented the anti-tumor response in 7/10
mice (total for two experiments) (Figure 5A)( P ,0.05 in the
growth curve and P,0.05 in the survival curve). To determine
whether direct CD8 T cell cytotoxicity was required for the CY-
induced anti-tumor response, we assessed the efficacy of CY in
perforin (pfp)-deficient mice. Perforin-deficiency did not abolish the
anti-tumor efficacy of CY (Figure 5B), and there was no
significant difference in survival (Figure 5B). It is important to
note that slightly larger tumors were treated in these experiments
(4–6 mm
2 instead of 1 mm
2 in other experiments), which has a
negative impact on the efficacy of CY. This explains why CY is
less efficacious in these experiments. Finally, we evaluated the
efficacy of CY in IFN-c/perforin double knock-out mice and
found that combined deficiency of IFN-c and perforin completely
abrogated the CY-induced anti-tumor effects (9/9 mice, two
experiments), consistent with the results from the IFN-c-knock-out
mice and highlighting the key role of this effector molecule
(Figure 5C). In fact, these tumors grew with similar kinetics as in
T-cell deficient nude mice (Figure 6B), consistent with our
previous data [18].
Role of TRAIL suggests a tumor cell sensitization model
As several chemotherapeutic drugs sensitize tumor cells for
death ligand-mediated cell apoptosis (TRAIL) [34], we analyzed
expression of the TRAIL receptor DR5 on AB1-HA tumor cells.
We could detect expression of DR5 on tumor cells (Figure 6A)
suggesting that TRAIL-mediated apoptosis could be involved in
the anti-tumor effects of CY. To evaluate the in vivo relevance of
TRAIL-mediated killing, tumor-bearing TRAIL-deficient mice
were treated with CY and tumor growth in these mice was
compared with immunocompetent mice. Analysis of tumor growth
curves revealed that TRAIL-deficiency indeed affected the anti-
tumor efficacy of CY (Figure 6B,P ,0.005), suggesting that
TRAIL could be an important effector molecule for anti-tumor
CD8 T cells. Athymic nude mice were used as a control to assess
the tumor growth rate in the absence of T cells.
Agonistic anti-DR5 antibodies rescue anti-tumor efficacy
in nude mice
A TRAIL-dependent tumor-resolution mechanism predicts that
the partial anti-tumor response of CY in athymic nude mice
(Figure 6B) [18] could potentially be rescued by mimicking
TRAIL-mediated tumor cell apoptosis. We tested this by
combining CY-treatment in nude mice with agonistic anti-DR5
antibodies (clone MD5-1) [35,36], reasoning that CY-sensitized
tumor cells would then be killed by antibody-mediated DR5
ligation, compensating for the lack of T cell derived TRAIL. Thus,
nude mice received a single dose of CY at day 9 post tumor cell
inoculation (tumor size 4–6 mm
2) and were treated with anti-DR5
on days 8, 12 and 16 post tumor cell inoculation. The results
clearly show that DR5-treatment alone was completely ineffective
and that CY alone had a very transient effect (Figure 7A). Note
that the single CY treatment in nude mice was suboptimal when
compared to earlier data (Figure 6B) [18], which can be
explained by the fact that these experiments were done with CY
injection at day 9 rather than day 7. Indeed, the CY efficacy in
athymic nude mice is very limited when larger (.161 mm)
tumors are treated, emphasizing the role of T cells. Indeed,
repetition of the experiment with CY-treatment done at day 7 and
anti-DR5 on days 6, 10 and 14 (Figure 7B) confirmed the benefit
of anti-DR5 antibodies in combination with CY and also increased
efficcy of earlier CY treatment (day 7 instead of 9). Combined, the
data clearly show that combination of CY with the agonistic anti-
DR5 antibody led to prolonged control of tumor growth
(Figure 7). Unfortunately, the CY/anti-DR5 combination
treatment was also associated with liver toxicity, preventing us
from studying long-term control of tumor growth [37]. TRAIL
blockade alone did not significantly affect the efficacy of CY in
nude mice, suggesting that the transient anti-tumor effect did not
depend on this mechanism (Figure 7B).
Discussion
The objective of the current study was to address the chemo/
immunotherapy paradox: how can CD8 T cells eradicate the
tumor when the chemotherapeutic drug antagonizes their
proliferation? We used CY in our AB1-HA malignant mesothe-
lioma model to address this issue because CY eliminates AB1-HA
tumors in a CD8 T cell-dependent fashion but depletes cycling T
cells at the same time. Our study makes four points. First, the
immune system (i.e., CD8 T cells and NK cells) is essential to
achieve curative responses after chemotherapy. This could suggest
that T cells and NK cells are required to prevent a small number
of chemotherapy-surviving tumor cells from re-establishing a new
tumor [38]. Second, the CY analogue maphosphamide induces
apoptosis in tumor cells, consistent with its direct cytotoxic effects
on AB1-HA tumor cells [18]. In vivo, the result of chemotherapy is
a systemic and long-lived type-I IFN response. Third, CY depleted
cycling Ki-67
hi T cells, blocked proliferation of CFSE-labeled
tumor-specific CD8 T cells and did not expand the endogenous
tumor-specific CD8 T cell response. Thus, the anti-tumor CD8
response after CY injection does not depend on proliferation for its
mode of action. Fourth, multiple effector functions were important
for tumor resolution: IFN-c and TRAIL. The role of TRAIL
suggests that CY sensitizes tumor cells for TRAIL-mediated
apoptosis. Thus, it is possible that anti-tumor CD8 T cells use IFN-
c and TRAIL to kill tumor cells. An intriguing possibility is that
TRAIL-mediated tumor cell killing contributes to immunogenic
cell death.
CY kills cells by inducing apoptosis and this seems to result in a
systemic type-I IFN response, confirming earlier studies [17,29,39]
and consistent with the notion of ‘immunogenic cell death’.
Similar data have been reported by Schiavoni and coworkers who
used expression of Ly6C on T cells (similar to Ly6AE) and PCR to
detect type-I IFN production [17]. Thus, we now confirm and
extend these observations. There may be two possible sources for
IFN production: the tumor cells themselves [29] and the
monocytes that phagocytose apoptotic tumor cells. There is direct
evidence for the former hypothesis [29], but the fact that cells
exposed to the CY-related drug melphalan activate phagocytosing
DCs [40] indicates that the latter may also occur. Irrespective of
the mechanism, type-I IFNs are essential to generate de novo CD8
T cell responses to apoptotic cells [8] and to cross-presented
Anti-Tumor Immune Response
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responses might augment potential anti-tumor CD8 T cell
responses. Indeed, this was the case in a MOPC-315 tumor
model in which CY induced type-I IFN-dependent tumor
regression [39]. However, CY-induced anti-tumor responses in
our model are clearly less dependent on type-I IFNs, in contrast to
the anti-tumor effects of poly-I:C and imiquimod in the same
model [5,23]. This indicates that CY mobilizes anti-tumor CD8 T
cells in a way that does not involve type-I IFN dependent
activation and/or expansion [30,41].
CY depletes proliferating CD8 T cells, and, as we have recently
shown, also CD4 T cells and foxp3+ regulatory CD4 T cells [18].
Figure 5. CD8 T cell effector mechanisms. (A) Tumor growth and Kaplan-Meier survival curves in CY-treated IFN-c-deficient mice and control
mice. Data shown are mean6SEM (n=5) from one experiment (growth curve, left panel) or total data from two experiments (survival curve, right
panel). Tumor cells were inoculated at day 0, treated with CY at day 9. * P,0.05 when CY in immunocompetent mice and IFN-c deficient mice is
compared. (B) Tumor growth curves and Kaplan-Meier survival curves in CY-treated perforin-deficient and normal control mice. ns=not significant
when CY in immuno-competent and perforin-deficient mice are compared. Tumor cells were inoculated at day 0 and treated with CY at day 8. ns, not
significant. (C) Tumor growth and Kaplan-Meier survival curves after CY treatment in perforin/IFN-c double-deficient mice, compared to
immunocompetent mice. Data shown are mean6SEM (n=5) from one experiment (growth curve, left panel) or total data from two experiments
(survival curve, right panel). Tumor cells were inoculated at day 0 and treated with CY at day 9. * P,0.05, *** P,0.001 when BALB/c + CY is compared
with IFN-c/pfp-ko + CY.
doi:10.1371/journal.pone.0006982.g005
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proliferating T cells, although several studies suggest that it may be
linked to increased numbers of NO-producing myeloid-derived
suppressor cells [42,43]. Whereas depletion of proliferating
regulatory T cell is beneficial [18,19,44], the impact of CY on
the CD8 T cell response could be negative and seems inconsistent
with the key role of CD8 T cells in tumor resolution. Our
explanation is that the importance of CY-triggered CD8 T cell
responses lies not so much in their total numbers, but rather in
their capacity to kill tumor cells. In this model, CY kills the
majority of tumor cells and sensitizes the remaining tumor cells for
T cell-mediated apoptosis, allowing the tumor-specific CD8 T cell
pool to become effective without the need for further expansion.
The benefit of regulatory T cell depletion [18,19,45,46] may be
that existing anti-tumor CD8 T cells are liberated from
suppression, allowing them to kill the sensitized tumor cells.
A tumor cell sensitization model [34] is supported by the key
role of TRAIL. Since no curative responses were ever observed in
athymic nude mice, it is evident that CY does not kill all tumor
cells. Therefore we propose that a subset of tumor cells that
receives a sublethal hit from the drug is sensitized for apoptosis by
agonistic anti-TRAIL-R (DR5) antibodies or tumor-specific CD8
T cells and most likely also NK cells. TRAIL sensitization of
tumor cells, including human mesothelioma cells, by chemother-
apeutic drugs has been well characterized [47,48] and has been
translated into therapeutic approaches involving soluble TRAIL
or other TRAIL-receptor agonists [35,49,50]. It has been
proposed that the synergy of TRAIL-ligation and chemotherapy
can be explained by integration of the intrinsic (through
chemotherapy) and alternative (death receptor) pathways of
apoptosis [47]. Recently, Johnstone and colleagues showed that
the histone diacetylase inhibitor vorinostat augmented the anti-
tumor effects of anti-DR5 antibodies in vivo and in vitro through
downregulation of the apoptosis inhibitor cellular-FLIP [51].
Similar in vitro data were shown earlier with cycloheximide and
sensitivity to TRAIL apoptosis [52]. TRAIL sensitivity can also be
increased through the proteasome inhibitor bortezomib [53]. The
liver toxicity that we observed in our current study seems
consistent with recent work showing that the drug 5-azacytidine
sensitizes hepatocytes for TRAIL apoptosis [54] and with a recent
study showing that DR5-mediated apoptosis of cholangiocytes
contributes to liver disease [37].
Increased TRAIL sensitivity explains why massive T cell
expansion is not necessary and why type-I IFNs are not required
for the anti-tumor effect in our model. Our data suggest that CD8 T
cells are a major source of TRAIL, since these cells are essential for
tumor resolution. NK cells may also be required [55]. A more precise
determination of the relative roles of NK cells and CD8 T cells and of
the source(s) of TRAIL will be the subject of further studies, which
should include measuring the in vitro sensitivity of maphosphamide-
treated tumor cells to DR5 ligation. The role of IFN-c could be
related to TRAIL, since both type-I and type-II IFNs have the
capacity to induce TRAIL expression [56,57] and anti-tumor
function [58]. The importance of TRAIL suggests that TRAIL
Figure 6. Role of TRAIL-mediated tumor cell apoptosis. (A) DR5 expression on AB1-HA tumor cells in vitro. (B) Tumor growth curves in CY-
treated and untreated TRAIL-deficient mice, compared with immunocompetent mice and nude mice. Data shown are mean6SEM (n=10) from two
combined experiments. Tumor cells were inoculated at day 0 and treated with CY at day 10. ** P,0.005 when CY in BALB/c is compared with CY in
TRAIL-deficient mice.
doi:10.1371/journal.pone.0006982.g006
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predict the efficacy of cancer vaccines or immunotherapies, possibly
equally important as perforin-mediated cell apoptosis and IFN-c.
Materials and Methods
Ethical statement
Animal experimentation was conducted according to University
of Western Australia Animal Ethics Committee approvals and the
NH&MRC code of conduct.
Reagents and antibodies
Cyclophosphamide, maphosphamide and gemcitabine were
from Sigma-Aldrich, Baxter Oncology (Halle, Germany) and the
Sir Charles Gairdner Hospital Pharmacy, respectively. FLIVO
caspase staining kits were from Immunochemistry Technologies
and used according to the instructions. Antibodies were from BD
Biosciences, eBioscience and Caltag: TCRb-AF488 (H57-597),
CD3e-FITC (145-2C11), CD4-PE/CD4-PECy7 (RM4-5), CD8-
PECy5/CD8-APC-AF750 (53–6.7), CD19-PECy7 (eBio1D3),
Ly6A/E-FITC (Sca1), Ki-67-FITC (B56), CD43-FITC (1B11)
and DR5-PE (MD5-1). Flow cytometry was performed on
FACSCalibur and FACSCanto II instruments and analyzed using
Flowjo (TreeStar).
Mice
Female BALB/c (H-2
d) wild-type and nude mice (6–8 wk old)
were purchased from the Animal Resources Centre (Canning
Vale, Australia). TCR transgenic CL4 mice, expressing a TCR
specific for the H-2
d-restricted peptide IYSTVASSL (residues
518–526) from the influenza virus A/PR8/8/34 HA protein, were
generated and screened as described [15]. TRAIL-deficient mice
were originally generated at Immunex Corporation [35,59] and
were backcrossed to BALB/c at the Peter MacCallum Cancer
Centre (Melbourne, Australia) (n=12). Perforin-IFN-c double-
deficient mice were bred at the Peter MacCallum Cancer Centre.
BALB/c perforin-deficient mice were originally generated at the
Peter MacCallum Cancer Centre [60] and bred at the Animal
Care Unit at UWA (Perth, Australia).
Tumor cell culture and inoculation
Generation and maintenance of the BALB/c-derived mouse
mesothelioma cell line AB1 and transfection with the HA gene
Figure 7. Rescue of CY anti-tumor efficacy in nude mice by anti-DR5 antibodies. Tumor-bearing athymic nude mice (inoculated at day 0)
were treated with CY or with PBS at day 9 (a) or day 7 (b) after tumor cell inoculation and were treated with anti-DR5 antibody (clone MD5-1) or PBS
at day 8, 12 and 16 after tumor cell inoculation. Data shown are mean6SEM (n=5/group for each experiment). * P,0.05 when CY is compared with
CY + anti-DR5. The effect of anti-TRAIL Ab without CY is shown in (b). Two mice were disqualified from the graph as they were found dead early in the
experiment.
doi:10.1371/journal.pone.0006982.g007
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6 in
PBS) were injected s.c. into the right flank of recipient mice and
tumor growth monitored using microcalipers. Mice were eutha-
nized when tumors reached 10610 mm as per Animal Ethics
guidelines.
Pentamer staining
For pentamer (ProImmune) staining, cells were blocked with
20 ml FCS (109, RT) after which 5 ml pentamer was added (309,
4uC). Cells were stained with mAbs against CD8 and TCRb and
anti-CD19 were included to reduce background.
Lyons-Parish analysis of Ag presentation
For CFSE (Molecular Probes) labeling, lymph node cells from
TCR-transgenic CL4 mice were incubated with 2.5 mM CFSE
(109 RT) and then centrifuged through a FCS cushion. A total of
1610
7 cells were injected i.v. into recipient mice. CFSE-labeled
cells were recovered 7 days after adoptive transfer and analyzed by
FACS.
In vivo antibody treatments
The IFN-a/b neutralizing sheep Ig and matching normal sheep
Ig [17,61] were used as described [5]. Mice were i.v. injected with
0.2 ml of immunoglobulins on day –1, +2, and +4 with respect to
CY administration. Monoclonal anti-IFN-c antibodies (clone
XMG 1.2) were purified from hybridoma supernatant and were
injected from day 7 after tumor cell inoculation onwards (q3dx4,
100 mg per injection). CD8a T cell depletion was performed using
purified YTS.169 monoclonal antibody (Dr Kathy Davern,
Monoclonal Antibody Facility, Western Australian Institute for
Medical Research) as previously described [5]. CD8 depletion
(.95%) was verified by FACS analysis of PBL. Agonistic anti-
DR5 antibody (clone MD5-1) [36] was injected i.p. at days -1, 3
and 7 relative to CY treatment (50 mg/injection). Neutralizing
TRAIL antibodies (clone N2B2) [36] were injected i.p. at days 21,
2, 5 and 8 relative to CY treatment (200 mg/injection).
Statistics
Data were statistically evaluated using Prism software (Graph-
Pad). Survival responses were analyzed by Kaplan-Meyer using
log-rank test. Growth curves were compared using a two-tailed
paired t test, with pairs defined by time point. Other variables
were compared using a two-tailed unpaired t test as indicated.
Survival curves were compared using the log rank test.
Significance was defined as p,0.05 and is indicated in the figures
and figure legends by asterisks.
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